# Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Source: https://onco.cc/trials/nct06526793/  
OnCo record `nct06526793` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AZD0486 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.

## Summary

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL is a phase 2 interventional study registered as NCT06526793 by AstraZeneca, with 270 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-04-21. Interventions recorded: Surovatamig. Conditions listed: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06526793
- Phase: 2
- Setting: A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
- Sponsor: AstraZeneca
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06526793: https://clinicaltrials.gov/study/NCT06526793

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AZD0486](https://onco.cc/drugs/azd0486/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06526793.json